MARKET

MTEM

MTEM

Molecular Templates Inc
NASDAQ
0.5906
-0.0164
-2.70%
Closed 13:27 11/25 EST
OPEN
0.6200
PREV CLOSE
0.6070
HIGH
0.6308
LOW
0.5906
VOLUME
77.17K
TURNOVER
0
52 WEEK HIGH
4.580
52 WEEK LOW
0.5400
MARKET CAP
33.28M
P/E (TTM)
-0.4112
1D
5D
1M
3M
1Y
5Y
Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI’s 5th Annual HealthCONx Conference and Piper Sandler’s 34th Annual Healthcare Conference
AUSTIN, Texas, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, ...
GlobeNewswire · 3d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 11/17 21:32
Molecular Templates Third Quarter 2022 Earnings: Beats Expectations
Molecular Templates ( NASDAQ:MTEM ) Third Quarter 2022 Results Key Financial Results Revenue: US$4.24m (up 78% from 3Q...
Simply Wall St. · 11/13 12:39
Barclays Maintains Overweight on Molecular Templates, Lowers Price Target to $1
Benzinga · 11/11 12:29
--Barclays Adjusts Price Target on Molecular Templates to $1 From $4.50, Maintains Overweight Rating
--Barclays Adjusts Price Target on Molecular Templates to $1 From $4.50, Maintains Overweight Rating
MT Newswires · 11/11 10:58
Molecular Templates Inc. (MTEM) Reports Q3 Loss, Tops Revenue Estimates
Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of 8.33% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/10 22:55
Molecular Templates GAAP EPS of -$0.44 beats by $0.04, revenue of $4.24M beats by $1.16M
Seekingalpha · 11/10 22:11
BRIEF-Molecular Templates Inc Reports Third Quarter 2022 Financial Results
Reuters · 11/10 21:44
More
About MTEM
Molecular Templates, Inc. is a clinical stage biopharmaceutical company that is focused on the discovery and development of differentiated, targeted, biologic therapeutics for cancer and other serious diseases. The Company utilizes its biologic drug platform to design and generate engineered toxin bodies (ETBs). ETBs use a genetically engineered version of the Shiga-like Toxin A subunit (SLTA), a ribosome inactivating bacterial protein. The Company is developing ETBs for various targets, including CD20, CD38, HER2, and PD-L1. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of multiple myeloma. HER2 is clinically validated as a target for the treatment of solid tumors including breast and gastric cancer. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers.

Webull offers kinds of Molecular Templates Inc stock information, including NASDAQ:MTEM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MTEM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MTEM stock methods without spending real money on the virtual paper trading platform.